ArticleJournal of food science2026
Antidiabetic Activity of Chickpea Albumin Hydrolysate in Streptozotocin-Induced Diabetic Rats.
Article in Journal of food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chickpea (Cicer arietinum L.) is a nutritious food that contains bioactive peptides with hypoglycemic and antihyperglycemic activities. This study evaluated the antidiabetic effects of chickpea albumin hydrolysate (CAH) in rats with hyperglycemia induced by a high-fat diet (HFD) and streptozotocin (STZ). The CAH peptide profile was analyzed by liquid chromatography‒mass spectrometry. Five groups (n = 6) were established: one healthy control (HC) and four diabetic groups: diabetic control (DC), metformin (500 mg/kg body weight, b.w.; MET), CAH (200 mg/kg b.w.; H200), and CAH (400 mg/kg b.w.; H400). Food intake, body weight, and fasting blood glucose (FBG) were assessed weekly, and an oral sucrose tolerance test (OSTT) was performed. Blood and liver were analyzed for biochemical parameters (glucose and lipid profile), renal (urea and creatinine) and hepatic function (AST, ALT, and ALP), oxidative stress markers (GSH and MDA), gluconeogenic (PEPCK and G6Pase), and pentose phosphate (G6PD) enzymes, and PI3K/AKT and AMPK signaling pathways. CAH presented peptides predicted to inhibit DPPIV and α-glucosidase. OSTT showed that CAH (H200 and H400) reduced blood glucose levels by 18.6% and 22.8%, respectively, while metformin reduced them by 41.6%. CAH and metformin improved the lipid profile, decreased urea and creatinine levels, and attenuated elevations in hepatic enzymes. They showed antioxidant effects by increasing GSH and reducing MDA levels. CAH-treated rats showed pancreatic tissue restoration, reduced PEPCK and G6Pase activities, and increased G6PD activity. Exploratory immunoblotting analyses revealed qualitative differences in the phosphorylation of AMPK (muscle and liver) and AKT (muscle), which may be associated with the metabolic effects of CAH. These findings suggest that chickpea bioactive peptides could be helpful in the management of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.